Research At a Glance
- Research Category
- Metabolic & Appetite Signaling Research
- Peptide Length
- 32 amino acids (amylin analogue, acylated)
- Purity
- ≥ 99% (HPLC)
- Published Studies
- ~90 indexed
- Storage
- Lyophilized: −20 °C long term, 2–8 °C short term. Reconstituted: 2–8 °C, use within 30 days.
Published-study figures are approximate PubMed result counts and indicate the volume of available literature only. Purity reflects third-party analytical testing on the corresponding lot; see the Quality Assurance Center for lot-matched certificates.
Scientific Overview
Cagrilintide (research designation AM833) is a long-acting synthetic analog of amylin, a hormone co-secreted with insulin by pancreatic beta cells that regulates satiety, gastric emptying, and postprandial glucose control. Unlike GLP-1 receptor agonists, cagrilintide acts on the amylin receptor complex (and possibly the calcitonin receptor), a mechanistically distinct pathway from the incretin system. Its structure includes stabilizing mutations that reduce fibril formation and a C-terminal modification for calcitonin receptor binding, along with a fatty-acid attachment — the same albumin-binding strategy used in semaglutide — that extends its half-life to support once-weekly research dosing. Cagrilintide is studied both as a standalone amylin-pathway compound and in combination with GLP-1 receptor agonists.
Lau D.C.W., et al., The Lancet, 2021 — search PubMed
Discovery & History
Cagrilintide was developed by Novo Nordisk as part of a research program exploring amylin-pathway agonism as a complement to GLP-1-based metabolic research. Its development built on earlier amylin-analog work with pramlintide, addressing that compound's short half-life through the same fatty-acid-conjugation strategy pioneered with semaglutide. Phase 1b and Phase 2 monotherapy studies (The Lancet, 2021) established the initial clinical research signal, which motivated the co-formulation with semaglutide studied under the name CagriSema in the REDEFINE trial program.
Enebo L.B., et al., The Lancet, 2021 — search PubMed
Molecular Structure
- CAS #
- 1415456-99-3
- Molecular Formula
- C194H312N54O59S2
- Molecular Weight
- ~4409 g/mol
- PubChem CID
- 171397054
Research Findings
Cagrilintide has been studied in monotherapy and combination-therapy trials for metabolic and weight-related research endpoints.
Key Areas of Research
- Metabolic: Amylin and calcitonin receptor activation, satiety signaling, postprandial glucose regulation.
- Gastrointestinal: Gastric emptying modulation.
- Neuroendocrine: Hindbrain area postrema satiety signaling, distinct from GLP-1 hypothalamic pathways.
- Combination research: Additive effects when studied alongside GLP-1 receptor agonists (CagriSema research program).
Summary
Together, these findings position cagrilintide as a mechanistically distinct research tool within metabolic peptide science — engaging the amylin/calcitonin receptor system rather than the incretin pathways studied with GLP-1 and GIP agonists. Because amylin and GLP-1 signaling are non-overlapping, cagrilintide is frequently studied in combination protocols examining additive or synergistic effects. It has not received FDA approval as a standalone or combination therapy as of this writing.
Lau D.C.W., et al., The Lancet, 2021
Scientific References
- Lau D.C.W., Erichsen L., Francisco A.M., et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. The Lancet.
- Enebo L.B., Berthelsen K.K., Kankam M., et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management. The Lancet.
Research Use Only
Provided for in-vitro laboratory research only. Not a drug, supplement, or cosmetic. Not for human or animal use.
Certificate of Analysis
Every lot is independently tested and lot-matched. View Certificates of Analysis